

CT
COPY OF PAPERS
ORIGINALLY FILED

RECEIVED 1653
JUL 10 2002
TECH CENTER 1600/2900
PH 3

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on May 13, 2002.

Donna L. Hengst

Donna L. Hengst

PATENT

Attorney Docket No. 12636-264



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>
Inventor(s): Joseph Rubinfeld)	
Application No.: 10/074,575)	Art Unit: Unassigned
Filed: February 11, 2002)	Examiner: Unassigned
Title Combination Therapy Including 9-Nitro-20(S)- And 5-Fluorouracil)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, can be found in priority Application No. 09/709,967, filed November 10, 2000, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

C.F.R. 1.98(d)

A copy of any patent publication other information listed in an information disclosure statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified and relied upon for an earlier filing dated under 35 U.S.C. 120.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

- ☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☒ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of 0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 12636-264).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: May 13. 2002

By: Shirley Chen

Shirley Chen, Reg. No. 44,608

650 Page Mill Road
Palo Alto, CA 94304-1050
(650) 493-9300
Customer No. 021971

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED
JUN 10 2002
TECH CENTER 1600/2900

SHEET 1 OF 2

INFORMATION DISCLOSURE CITATION PTO-1449		ATTY. DOCKET NO. 12636-264		SERIAL NO. 10/074,575			
		APPLICANT Joseph Rubinfeld					
		FILING DATE 02/11/02		GROUP Unassigned			
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	5,786,344	07/28/98	Ratain et al.	514	100		
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Bernacki, Ralph J. et al., "In Vitro Antitumor Activity of 9-Nitro-Camptothecin as a Single Agent and in Combination with other Antitumor Drugs", Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, AAN, N.Y. ACAD. SCI., vol. 922, 2000, pp. 293-297							
Karaberis, E. and D. Mourelatos, "Enhanced Cytogenetic and Antitumor Effects by 9-Nitrocarnptothecin and Antineoplastics", Laboratory of Biology and Genetics, Medical School, Aristotle University, Thessaloniki, Greece, TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS, vol. 20, no. 3, 2000, pp. 141-146							
Dainiak, Nicholas et al., "DNA Topoisomerase Inhibitors Block Erythropoiesis and Delay Hemoglobinization In Vitro", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 138, no. 1, 1989, pp. 87-96							
Drewinko, B et al., "Combination Chemo Therapy In-Vitro with Adriamycin Observations of Additive Antagonistic and Synergistic Effects When Used in 2 Drug Combinations on Cultured Lymphoma Cells", CANCER BIOCHEMISTRY BIOPHYSICS, vol. 1, no. 4, 1976, pp. 187-195							
Kaufmann, Scott H. "Antagonism between Camptothecin and Topoisomerase II-directed Chemotherapeutic Agents in a Human Leukemia Cell Line", CANCER RESEARCH, vol. 51, no. 4, 1991, pp. 1129-1136							
Guichard, Sylvie et al., "Cellular Interactions of 5-Fluorouracil and the Camptothecin Analogue CPT-11 (Irinotecan) in a Human Colorectal Carcinoma Cell Line" BIOCHEMICAL PHARMACOLOGY, vol. 55, no. 5, March 1, 1998, pp. 667-676							
Ciesielski, M.J. et al., "Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation" JOURNAL OF NEURO-ONCOLOGY, 1999, 41/3, pp. 223-234							
Giovanella, B.C. et al., "Enhanced antitumor effectiveness of camptothecin (CPT) and derivatives administered by continuous infusion through scheduling and combination with DNA damaging agents." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 36, March 1991, p 391							
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION OFFICE PTO-1449		ATTY. DOCKET NO. 12636-264		SERIAL NO. 10/074,575			
		APPLICANT Joseph Rubinfeld					
		FILING DATE 02/11/02		GROUP Unassigned			
		U.S. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
Database WPI, Section Ch, Week 199309, Derwent Publications Ltd., London, GB, Class B02, AN 1993-071029							
Takimoto, Chris H. and Susan G. Arbus, "The Camptothecins", CANCER CHEMOTHERAPY AND BIOTHERAPY, 1996, Chabner, Philadelphia, pp. 463-484							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.